Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT

Blood Adv. 2021 Jan 12;5(1):66-70. doi: 10.1182/bloodadvances.2020003366.

¹ College of Pharmacy, The Ohio State University, Columbus, OH.
² Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
³ Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD.
⁴ Department of Medicine, Roswell Park Comprehensive Cancer Institute, Buffalo, NY.
⁵ Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
⁶ Department of Preventive Medicine, University of Southern California, Los Angeles, CA.
⁷ Center for International Blood and Marrow Transplant Research, Minneapolis, MN.
⁸ Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.
⁹ Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI.
¹⁰ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
¹¹ Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC; and.
¹² College of Veterinary Medicine, The Ohio State University, Columbus, OH.

Abstract

Pre-HCT mosaicism is related to increased relapse risk and lower survival after unrelated HCT, independent of cytogenetics at diagnosis.
Pre-HCT mosaicism could be a useful clinical tool to guide risk stratification in acute lymphoblastic leukemia patients.